Apremilast as a treatment for morphea: A case series
Merav Koschitzky, Saakshi Khattri
Abstract
Morphea, or localized scleroderma, is a skin condition characterized by erythematous and indurated inflammatory lesions that progress to atrophic and sclerotic plaques.1 While the pathogenesis of morphea is complex, the fibrosis in morphea is believed to be immune-driven.2 A recent study showing the anti-fibrotic effects of the phosphodiesterase 4 (PDE4) inhibitor apremilast in preclinical models of skin fibrosis suggested that patients with inflammation-driven fibrosis might respond to PDE4 inhibition.
Topics & Concepts
MorpheaApremilastMedicineLocalized SclerodermaFibrosisScleroderma (fungus)DermatologyPathogenesisPsoriasisInflammationPathologyImmunologyInoculationLichen sclerosusPsoriatic arthritisSystemic Sclerosis and Related DiseasesMast cells and histamineAutoimmune Bullous Skin Diseases